AstraZeneca at the 2017 European Respiratory Society International Congress

At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines, along with scientific research focused on three key areas: lung immunity, lung epithelium and lung regeneration. We are excited to join clinicians, researchers and scientists at the 2017 European Respiratory Society (ERS) International Congress to share the latest in respiratory science advancements.

Follow us on Twitter @AstraZeneca and join the conversation using #ERSCongress.

Investors and analysts can join the AstraZeneca ERS investor science event and webcast

Advancing the understanding of the role of eosinophils in respiratory care

Expand the GIFs to learn more about how understanding blood eosinophil levels and related patient characteristics may help guide clinical practice and treatment choice in COPD and asthma.


In asthma

Looking into our labs

What are our respiratory scientists uncovering in our early science unit labs?  Hear more about their research into the true disease drivers of asthma and COPD. These are the people pushing the boundaries of science so we can deliver the next generation of medicines focused on disease modification, early intervention and even the potential for cures.

Understanding drivers of inflammation in severe asthma

Evolving clinical practice

Veeva ID: Z4-6921
Date of next review: September 2018